21 C.F.R. Subpart B—Reimportation
Title 21 - Food and Drugs
No prescription drug or drug composed wholly or partly of insulin that was manufactured in a State and exported from the United States may be reimported by anyone other than its manufacturer, except that FDA may grant permission to a person other than the manufacturer to reimport a prescription drug or insulin-containing drug if it determines that such reimportation is required for emergency medical care. (a) Applications for reimportation for emergency medical care shall be submitted to the director of the FDA District Office in the district where reimportation is sought (addresses found in part 5, subpart M of this chapter). (b) Applications for reimportation to provide emergency medical care shall be reviewed and approved or disapproved by each district office. [64 FR 67756, Dec. 3, 1999, as amended at 69 FR 17292, Apr. 2, 2004] An appeal from an adverse decision by the district office involving insulin-containing drugs or prescription human drugs, other than biological products, may be made to the Office of Compliance (HFD–300), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. An appeal from an adverse decision by the district office involving prescription human biological products may be made to the Office of Compliance and Biologics Quality (HFM–600), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852 or the Office of Compliance (HFD–300), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, depending on the Center responsible for regulating the product. [64 FR 67756, Dec. 3, 1999, as amended at 69 FR 48775, Aug. 11, 2004; 70 FR 14980, Mar. 24, 2005]
Title 21: Food and Drugs
PART 203—PRESCRIPTION DRUG MARKETING
Subpart B—Reimportation
§ 203.10 Restrictions on reimportation.
§ 203.11 Applications for reimportation to provide emergency medical care.
§ 203.12 An appeal from an adverse decision by the district office.
